Xeltis’ restorative coronary artery bypass graft (CABG), the XABG device, featured at two podium presentations at 2021 European Association for Cardio-Thoracic Surgery (EACTS) annual meeting.
In a session about the science behind the future of coronary and vascular conduits, XABG’s outstanding one-year preclinical data have been presented on Friday 15 October. The trial outcomes provide insights into the device’s excellent patency and remodelling, and on its performance, including the correlation between early biomechanical factors and flow ratio
“The outstanding outcomes in animal models of the XABG device clearly indicate that we are potentially at the forefront of the future for CABG surgery. With vein harvesting potentially becoming unnecessary, we may be offering patients quicker surgical procedures, prompter recovery and lower risk of complications thereafter,” stated professor Patrick Serruys, CORRIB Research Centre for Advanced Imaging and Core Laboratory at National University of Ireland Galway, who has been collaborating with Xeltis intensively to investigate the XABG’s preclinical potential.
Now in its 35th edition, EACTS annual meeting is the largest event for the cardiothoracic community in Europe.
